⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Grifols, S.A. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Grifols, S.A.
↗Sant Cugat del Vallès (Barcelona), Spain
Grifols is a global healthcare company and a pioneer in the plasma industry, founded in 1909. It specializes in the development, production, and provision of innovative plasma-derived medicines and biopharmaceutical solutions to treat chronic, rare, and life-threatening conditions.
The company operates a vast network of plasma donation centers globally and provides diagnostic technologies, transfusion medicine solutions, and biological supplies for life-science research. Grifols is committed to a sustainable business model, focusing on innovation, quality, and safety across its operations in more than 110 countries.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Plasma-derived therapeutics and diagnostics
SIZE & FINANCIALS
Employees:10000+
Revenue:€7.2B (2024)
Founded:1909
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ|BMAD
Ticker:GRFS (NASDAQ), GRF (BMAD)
Market Cap:$6.6B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Plasma-derived proteins, Recombinant antibodies, Small molecule
Active Trials:0
Trial Phases:Phase 2: 9 | Phase 3: 6
FDA Approvals:17
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Biotest (majority stake)
Key Partnerships:Shanghai RAAS (plasma collection in China), FcR Therapeutics (recombinant therapies)
COMPETITION
Position:Leader
Competitors:CSL Behring, Takeda, Octapharma
LEADERSHIP
Key Executives:
Nacho Abia - CEO
LINKS
Website:grifols.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Grifols, S.A.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.